Augmedix Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	44.86	30.93	22.17	16.48	14.11	10.82
Revenue Growth (YoY)	45.01%	39.56%	34.47%	16.84%	30.44%	-
Cost of Revenue	23.33	16.98	12.16	9.69	9.43	10.03
Gross Profit	21.53	13.95	10.01	6.79	4.68	0.79
Selling, General & Admin	29.13	26.18	20.88	15.97	14.44	16.75
Research & Development	11.18	10.15	6.68	4.52	6.98	6.96
Operating Expenses	40.31	36.33	27.56	20.49	21.42	23.71
Operating Income	-18.78	-22.37	-17.55	-13.69	-16.74	-22.92
Interest Expense / Income	2.25	1.68	2.25	1.45	2.81	2.08
Other Expense / Income	-2.01	0.29	-2.39	0.46	-1.06	-0.84
Pretax Income	-19.03	-24.34	-17.42	-15.6	-18.5	-24.16
Income Tax	0.15	0.11	0.05	0	0	0
Net Income	-19.17	-24.45	-17.46	-15.6	-18.5	-24.16
Shares Outstanding (Basic)	44	37	29	7	1	1
Shares Outstanding (Diluted)	44	37	29	7	1	1
Shares Change	17.45%	29.41%	311.09%	745.81%	-30.08%	-
EPS (Basic)	-0.44	-0.65	-0.60	-2.22	-22.24	-20.32
EPS (Diluted)	-0.44	-0.65	-0.60	-2.22	-22.24	-20.32
Free Cash Flow	-18.55	-18.18	-19.2	-15.05	-15.47	-20.24
Free Cash Flow Per Share	-0.42	-0.49	-0.66	-2.14	-18.60	-17.01
Gross Margin	47.99%	45.11%	45.15%	41.22%	33.17%	7.27%
Operating Margin	-41.87%	-72.32%	-79.18%	-83.07%	-118.68%	-211.94%
Profit Margin	-42.74%	-79.04%	-78.79%	-94.67%	-131.12%	-223.41%
Free Cash Flow Margin	-41.35%	-58.78%	-86.64%	-91.28%	-109.65%	-187.11%
EBITDA	-14.63	-21.14	-14.47	-13.28	-14.74	-20.49
EBITDA Margin	-32.62%	-68.33%	-65.30%	-80.59%	-104.46%	-189.47%
Depreciation & Amortization	2.14	1.53	0.69	0.87	0.95	1.59
EBIT	-16.77	-22.66	-15.17	-14.15	-15.69	-22.08
EBIT Margin	-37.39%	-73.26%	-68.42%	-85.85%	-111.19%	-204.15%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).